AU2012351342A1 - Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis - Google Patents

Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis Download PDF

Info

Publication number
AU2012351342A1
AU2012351342A1 AU2012351342A AU2012351342A AU2012351342A1 AU 2012351342 A1 AU2012351342 A1 AU 2012351342A1 AU 2012351342 A AU2012351342 A AU 2012351342A AU 2012351342 A AU2012351342 A AU 2012351342A AU 2012351342 A1 AU2012351342 A1 AU 2012351342A1
Authority
AU
Australia
Prior art keywords
methyl
acetic acid
fluoro
indol
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012351342A
Other languages
English (en)
Inventor
Mark Anthony Payton
Eric Roy Pettipher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atopix Therapeutics Ltd
Original Assignee
Atopix Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atopix Therapeutics Ltd filed Critical Atopix Therapeutics Ltd
Publication of AU2012351342A1 publication Critical patent/AU2012351342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2012351342A 2011-12-16 2012-12-14 Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis Abandoned AU2012351342A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576640P 2011-12-16 2011-12-16
US61/576,640 2011-12-16
PCT/GB2012/000904 WO2013088109A1 (en) 2011-12-16 2012-12-14 Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis

Publications (1)

Publication Number Publication Date
AU2012351342A1 true AU2012351342A1 (en) 2014-07-24

Family

ID=47470031

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012351342A Abandoned AU2012351342A1 (en) 2011-12-16 2012-12-14 Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis

Country Status (14)

Country Link
US (1) US20140328861A1 (pt)
EP (1) EP2790696A1 (pt)
JP (1) JP2015500326A (pt)
KR (1) KR20140113667A (pt)
CN (1) CN104114169A (pt)
AU (1) AU2012351342A1 (pt)
BR (1) BR112014014558A8 (pt)
CA (1) CA2859284A1 (pt)
EA (1) EA026456B1 (pt)
IL (1) IL233131A0 (pt)
MX (1) MX2014007239A (pt)
SG (1) SG11201402796SA (pt)
UA (1) UA112667C2 (pt)
WO (1) WO2013088109A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
PT3470432T (pt) 2012-08-21 2021-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
AU2014284235B2 (en) 2013-06-21 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CN106062000B (zh) 2014-02-28 2021-05-28 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗皮肤感染的方法
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US10066017B2 (en) 2014-11-14 2018-09-04 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
EP3402572B1 (en) * 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
CA3031350A1 (en) * 2016-07-21 2018-01-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indole derivative used as crth2 inhibitor
TWI777515B (zh) * 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
KR102462039B1 (ko) 2016-09-01 2022-11-02 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MA46269B1 (fr) 2017-08-18 2024-05-31 Regeneron Pharma Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
EP4344706A3 (en) 2017-10-30 2024-05-22 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CN107987072B (zh) * 2017-11-30 2020-06-26 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类化合物
CN107954995B (zh) * 2017-11-30 2020-05-05 正大天晴药业集团股份有限公司 具有crth2抑制剂活性的吲哚衍生物
CN107936004B (zh) * 2017-11-30 2020-05-05 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚类衍生物
CN107987066B (zh) * 2017-11-30 2020-06-26 正大天晴药业集团股份有限公司 作为crth2抑制剂的吲哚衍生物
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
BR112020020387A2 (pt) 2018-05-13 2021-01-19 Regeneron Pharmaceuticals, Inc. Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r
BR112021018627A2 (pt) 2019-03-21 2021-11-23 Regeneron Pharma Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
WO2022020464A1 (en) * 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
ATE327977T1 (de) 2002-10-21 2006-06-15 Warner Lambert Co Tetrahydrochinolin-derivate als crth2 antagonisten
AU2003297398B2 (en) 2002-12-20 2009-09-24 Amgen Inc. Asthma and allergic inflammation modulators
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2005007094A2 (en) 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
JP2007508363A (ja) 2003-10-14 2007-04-05 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
PT1718649E (pt) 2004-01-31 2009-08-06 Actimis Pharmaceuticals Inc Derivados de ácido imidazo[1,2-c]pirimidinilacético
EP1740171B1 (en) 2004-03-11 2010-06-09 Actelion Pharmaceuticals Ltd. Indol-1-yl-acetic acid derivatives
CN1930162B (zh) 2004-03-11 2010-06-16 埃科特莱茵药品有限公司 四氢吡啶并吲哚衍生物
EP1740547A1 (en) 2004-04-07 2007-01-10 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
EP1758571A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for therapeutic use
EA200602288A1 (ru) 2004-05-29 2007-10-26 7ТиЭм ФАРМА А/С Замещённые тиазолуксусные кислоты в качестве лигандов crth2
JP2008500991A (ja) 2004-05-29 2008-01-17 ７ティーエム ファーマ エイ／エス 医学的使用のためのｃｒｔｈ２レセプターリガンド
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
WO2006034419A2 (en) 2004-09-21 2006-03-30 Athersys, Inc. Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
PT1817282E (pt) 2004-11-23 2011-09-19 Astrazeneca Ab Derivados do ácido fenoxiacético úteis para tratar doenças respiratórias
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
UA90706C2 (ru) 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
EP1871374B1 (en) 2005-04-21 2011-09-14 Merck Serono SA 2,3 substituted pyrazine sulfonamides as inhibitors of crth2
EP1891075B1 (en) 2005-05-24 2011-10-19 Merck Serono SA Tricyclic spiro derivatives as crth2 modulators
GB0510585D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
EP1747800B1 (en) * 2005-07-29 2009-03-18 Rottapharm S.p.A. Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
US20070203209A1 (en) 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
GB0518494D0 (en) 2005-09-09 2005-10-19 Argenta Discovery Ltd Thiazole compounds
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
NZ566537A (en) 2005-09-30 2010-10-29 Pulmagen Therapeutics Asthma L Quinolines and their therapeutic use
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
JP2009514935A (ja) 2005-11-05 2009-04-09 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007062678A1 (en) 2005-11-29 2007-06-07 7Tm Pharma A/S Phenoxyacetic acid derivatives as crth2 receptor ligands
WO2007062677A1 (en) 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
GB0524427D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Use of receptor ligands in threapy
US20080293775A1 (en) 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
US7741360B2 (en) 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
GB0611781D0 (en) 2006-06-14 2006-07-26 Argenta Discovery Ltd 2-Oxo-2H-Chromene Compounds
JP5270542B2 (ja) 2006-07-22 2013-08-21 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
KR101397352B1 (ko) 2006-08-21 2014-05-19 어레이 바이오파마 인크. 4-치환된 페녹시페닐아세트산 유도체
MX2009006762A (es) 2006-12-21 2009-08-20 Argenta Discovery Ltd Antagonistas crth2.
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
EA200970875A1 (ru) 2007-03-21 2010-04-30 Арджента Орал Терапьютикс Лимитед Производные индолизинуксусной кислоты в качестве антагонистов crth2
BRPI0721516A2 (pt) 2007-03-29 2013-01-15 Argenta Discovery Ltd derivados de quinolina como ligantes de receptor crth2
EP2176240A1 (en) 2007-06-21 2010-04-21 Actimis Pharmaceuticals, Inc., Amine salts of a crth2 antagonist
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
US20110124683A1 (en) 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
CN101970405A (zh) * 2007-12-14 2011-02-09 普尔马金医疗(哮喘)有限公司 吲哚及其治疗用途
ES2471919T3 (es) 2007-12-19 2014-06-27 Amgen, Inc Derivados de ácido fenilac�tico como moduladores de inflamación
RU2503672C2 (ru) * 2008-01-18 2014-01-10 Оксаген Лимитед Соединения, обладающие активностью антагонистов crth2
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509990A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
EP2300425A4 (en) * 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
US20110312945A1 (en) * 2008-10-01 2011-12-22 James Jia Crth2 modulators
US8524748B2 (en) * 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
US8530500B2 (en) * 2009-07-20 2013-09-10 Vetegen, Llc Stable pharmaceutical omeprazole formulation for oral administration
CA2768587A1 (en) 2009-08-05 2011-02-10 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
JP5838158B2 (ja) * 2009-08-17 2015-12-24 ザ・ペン・ステート・リサーチ・ファンデーション 心血管疾患、および２型糖尿病などの代謝疾患の治療のためのｎｋｇ２ｄ阻害剤の使用
AU2011203649A1 (en) 2010-01-06 2012-06-14 Brickell Biotech, Inc. DP2 antagonist and uses thereof

Also Published As

Publication number Publication date
EP2790696A1 (en) 2014-10-22
JP2015500326A (ja) 2015-01-05
EA026456B1 (ru) 2017-04-28
UA112667C2 (uk) 2016-10-10
IL233131A0 (en) 2014-07-31
KR20140113667A (ko) 2014-09-24
CN104114169A (zh) 2014-10-22
WO2013088109A1 (en) 2013-06-20
BR112014014558A2 (pt) 2017-06-13
CA2859284A1 (en) 2013-06-20
NZ626990A (en) 2016-01-29
BR112014014558A8 (pt) 2017-07-04
MX2014007239A (es) 2014-08-08
SG11201402796SA (en) 2014-06-27
EA201491008A1 (ru) 2015-02-27
US20140328861A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
AU2012351342A1 (en) Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US9598400B2 (en) Substituted quinoline compounds and methods of use
JP7235816B2 (ja) 核内受容体調節剤
JP2023052343A (ja) インダゾール－３－カルボキサミドの使用方法およびｗｎｔ／β－カテニンシグナル伝達経路阻害剤としてのそれらの使用
JP6342393B2 (ja) 置換型ピラゾロン化合物及び使用方法
JP5827627B2 (ja) ＴＧＦ−β受容体キナーゼ阻害剤としてのヘテロアリールアミノキノリン
JP2018021065A (ja) １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびそれらの治療的使用
KR20180013851A (ko) 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물
AU2012223639A1 (en) Substituted quinoline compounds and methods of use
KR20180013850A (ko) 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
JP2024072291A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
KR20150083833A (ko) Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 및 이의 이용 방법
KR20150118102A (ko) Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
WO2018178679A1 (en) Combination of isoindolinone derivatives with sgi-110
JP7319314B2 (ja) アザ二環式化合物を用いたがん化学療法
RU2020120538A (ru) Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
US20230263801A1 (en) Combination therapy of parp inhibitors
JP2023548657A (ja) がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤
NZ626990B2 (en) Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CN117500803A (zh) 用于治疗具egfr突变的癌症的氨基取代杂环
RU2023127295A (ru) Производные индолина в качестве ингибиторов ddr
AU2018208662A1 (en) Methods and Compositions for Treating Schizophrenia
CA2478958A1 (en) Use of proton pump inhibitors for the treatment of airway disorders

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period